Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mereo Biopharma Group Plc ( (MREO) ) has shared an update.
On May 14, 2026, Mereo BioPharma Group plc held its 2026 Annual General Meeting, at which all proposed resolutions were passed, with 436,766,255 ordinary shares represented in person or by proxy. Shareholders adopted the 2025 annual report and accounts, reappointed PricewaterhouseCoopers LLP as auditor, authorized the Audit and Risk Committee to set auditor remuneration for 2026, and approved the directors’ remuneration report, remuneration policy and advisory compensation for named executive officers.
Investors also backed the reappointment of directors Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz, reinforcing continuity in board leadership. In addition, shareholders renewed and extended authorities for the board to allot shares and to issue shares for cash on a non-pre-emptive basis until June 30, 2029, providing the company with flexibility to raise equity capital and manage its financing strategy, although these capital authorities drew comparatively higher opposition than other resolutions.
The most recent analyst rating on (MREO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Mereo Biopharma Group Plc stock, see the MREO Stock Forecast page.
Spark’s Take on MREO Stock
According to Spark, TipRanks’ AI Analyst, MREO is a Neutral.
The score is weighed down primarily by weak financial performance (large losses and continued cash burn) and a bearish technical setup (price below key moving averages with negative MACD). A low-debt balance sheet provides some stability, but valuation is constrained by negative earnings and a negative corporate event (Nasdaq bid-price noncompliance) adds downside risk.
To see Spark’s full report on MREO stock, click here.
More about Mereo Biopharma Group Plc
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing and commercializing innovative therapeutics. Operating in the life sciences sector, the company concentrates on addressing unmet medical needs through a pipeline of drug candidates, positioning itself within the competitive global biotech and pharma industry.
Average Trading Volume: 1,771,964
Technical Sentiment Signal: Sell
Current Market Cap: $39.27M
For an in-depth examination of MREO stock, go to TipRanks’ Overview page.